Other substances

Crocetin

A natural vitamin A analogue.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
2
 Clinical trials

General information

Crocetin on PubChem

Synonyms

8,8'-Diapocarotenedioic acid

 

Structure image - Crocetin

C/C(=C\C=C\C=C(\C=C\C=C(\C(=O)O)/C)/C)/C=C/C=C(/C(=O)O)\C

Supporting references

Link Tested on Impact factor Notes Publication date
Investigation on penetration of saffron components through lipid bilayer bound to spike protein of SARS-CoV-2 using steered molecular dynamics simulation
3CLpro Small molecule In silico 		in silico

Predicted to bind the SARS-CoV-2 3C-like protease and have the capability to cross the lipid bilayer.

 Dec/12/2020

AI-suggested references

Link Publication date
Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation
Jun/24/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04378920 A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes Completed Phase 1|Phase 2 Apr/14/2020 Aug/24/2021
  • Alternative id - 2020-003|2020-001393-30|2020-A00900-39
  • Interventions - Drug: LEAF-4L6715
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut de cancérologie Strasbourg Europe, Strasbourg, France
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 37
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio|proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg|all cause mortality
NCT04573322 Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects Completed Phase 1|Phase 2 Sep/10/2020 Apr/29/2021
  • Alternative id - 100-303
  • Interventions - Drug: Trans Sodium Crocetinate|Drug: Normal saline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - National Institute of Infectious Diseases- Prof. Dr. Matei Balş, Bucharest, Romania
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 25
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Time to recovery through Day 28|WHO Ordinal Severity Scale|WHO Ordinal Severity Scale - Time to Improvement|WHO Ordinal Severity Scale - Change from Baseline|National Early Warning Score (NEWS)|National Early Warning Score (NEWS) - Change from Baseline|Mechanical Ventilation|Mechanical Ventilation - Duration|Hospitalization|Oxygenation|Oxygenation - New Oxygen Use|Oxygenation - Advanced Therapies|Oxygenation - Time to Return to Baseline|Oxygenation - Pulse Oximetry|Oxygenation - ABG Measurements|Mortality
Export (.csv)